Qeli Etleva, Toti Çeljana, Odorici Alessandra, Blasi Elisabetta, Tragaj Emiljano, Tepedino Michele, Masedu Francesco, Kaçani Gerta, Hysi Dorjan, Meto Agron, Fiorillo Luca, Meto Aida
Department of Conservative, Faculty of Dental Medicine, University of Medicine, 1005 Tirana, Albania.
Department of Prosthetic, Faculty of Dental Medicine, University of Medicine, 1005 Tirana, Albania.
Materials (Basel). 2022 Feb 8;15(3):1266. doi: 10.3390/ma15031266.
Hyperesthesia is related to increased sensitivity of dental tissues to mechanical, chemical and thermal stimuli. The aim of this prospective clinical trial was to compare the effectiveness of a calcium-fluoride-forming agent (Tiefenfluorid, Humanchemie GmbH, Alfeld, Germany) with that of a fluoride varnish (Enamelast, Ultradent Inc., Cologne, Germany) in the treatment of dental hyperesthesia in adult patients. In total, 176 individuals (106 females and 70 males, aged 18-59 years old) diagnosed with dental hyperesthesia (DH) were enrolled. The main clinical symptoms were hyperesthesia from coldness and sweetness during chewing; the types of clinical lesions were also determined and recorded. The patients were selected randomly and divided into two groups: (i) the first group of 96 patients was treated with Tiefenfluorid applied in three appointments at 7-day intervals; (ii) the second group of 80 patients was treated with Enamelast, applied seven times at 7-day intervals. All the patients were recalled 7 days, 14 days, 1 month, 3 months, and 6 months from the last application. At the baseline and during every follow-up visit, the DH was measured with a pulp tester. A random intercept/random slope model was used to evaluate the effect of the treatment, at various times with respect to the initial diagnosis. Within the limits of the present study, Tiefenfluorid was more effective than Enamelast against DH in that it provided long-lasting results, with a significant improvement still detected at the latest 6-month follow-up.
牙本质过敏症与牙体组织对机械、化学和热刺激的敏感性增加有关。这项前瞻性临床试验的目的是比较一种形成氟化钙的制剂(Tiefenfluorid,德国阿尔费尔德市Humanchemie GmbH公司)与一种氟化物 varnish(Enamelast,德国科隆市Ultradent Inc.公司)在治疗成年患者牙本质过敏症方面的有效性。总共招募了176名被诊断为牙本质过敏症(DH)的个体(106名女性和70名男性,年龄在18至59岁之间)。主要临床症状为咀嚼时对冷和甜的过敏;还确定并记录了临床病变类型。患者被随机选择并分为两组:(i)第一组96名患者接受Tiefenfluorid治疗,分三次给药,间隔7天;(ii)第二组80名患者接受Enamelast治疗,每隔7天给药7次。所有患者在最后一次用药后的7天、14天、1个月、3个月和6个月进行回访。在基线期和每次随访时,使用牙髓活力测试仪测量牙本质过敏症情况。采用随机截距/随机斜率模型来评估治疗效果,在初始诊断后的不同时间点进行评估。在本研究的范围内,Tiefenfluorid在治疗牙本质过敏症方面比Enamelast更有效,因为它能提供持久的效果,在最晚的6个月随访时仍能检测到显著改善。